Eli Lilly requests for EUA approval from FDA for COVID-19 antibody
Category: #health  By Nikita Chaurasia  Date: 2020-10-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Eli Lilly requests for EUA approval from FDA for COVID-19 antibody

Eli Lilly and Company, the American pharmaceutical giant, has reportedly applied for emergency use authorization (EUA) for its potential COVID-19 antibody from the Food & Drug Administration (FDA). Sources with knowledge of the matter stated that the company has applied for EUA based on its previous study results and new information.

For those unfamiliar, Eli Lilly has developed a monoclonal antibody combination therapy called LY-CoV555 in order to treat the patients suffering from mild-to-moderate COVID-19. The company claims that its experimental antibody can help in reducing the virus level in the body as well as the overall hospitalization rates.

According to credible sources, the Phase 2 trials of the potential antibody comprised of around 112 people while up to 156 individuals were given a placebo. In this context, Eli Lilly specified that the patients who received the antibody therapy witnessed a significant decline in their virus levels after three to seven days.

Moreover, the company stated that over 0.9% of the patients on treatment went to emergency room or were hospitalized. Around 5.8% of the patients on placebo were apparently hospitalized as well.

Professor of pharmacoepidemiology at London School of Hygiene & Tropical Medicine, Stephen Evans was reported saying that although the data of phase 2 trials is encouraging, the experimental drug is still at preliminary stage. He further mentioned that the evidence derived from LY-CoV555 trials is not effective and needs to be studied more.

It is to be noted that Eli Lilly plans to produce over 1 million doses of its potential vaccine after receiving FDA authorization for its emergency use against the virus.

In other news, the FDA has reportedly informed the pharmaceutical companies to provide two months of safety data before authorizing the emergency use of their respective vaccines.

Source credits-

https://edition.cnn.com/2020/10/07/health/eli-lilly-antibody-therapy-results-eua/index.html

https://www.news18.com/news/world/u-s-fda-safety-guidelines-likely-to-push-covid-19-vaccine-authorization-past-election-2939275.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Facebook sued for failing to protect data in Cambridge Analytica breach
Facebook sued for failing to protect data in Cambridge Analytica breach
By Nikita Chaurasia

  The group taking the social media giant to court is ‘Facebook You Owe Us’. Facebook claims to have not received any documents pertaining to the lawsuit. American social media conglomerate Facebook Inc. has reportedly been sue...

Sony witnesses high demand for Play Station 5 through preorders
Sony witnesses high demand for Play Station 5 through preorders
By Nikita Chaurasia

Japanese multinational conglomerate Sony Corporation has reportedly witnessed a high demand for its PlayStation 5 (PS5) console with the pre-orders coming in at an unexpected pace. Market analysts claim that the company intends to lead the competiti...

London’s gearing up to deliver Covid-19 vaccine as early as next week
London’s gearing up to deliver Covid-19 vaccine as early as next week
By Nikita Chaurasia

The George Eliot Hospital NHS Trust, Warwickshire, is likely to receive the first batches of AstraZeneca’s and Oxford’s coronavirus vaccine on 2nd November. The revelation comes along the heels of directive to George Eliot Hospital NHS T...